Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.

Peer-Reviewed Articles

1. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget 8(22):35656-35668, 2017. e-Pub 2016. PMID: 27374101.
2. Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea M, Ueno NT, Creighton CJ, Sen S. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis 37(12):1180-1189, 2016. e-Pub 2016. PMID: 27624071.
3. Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat 160(1):101-109, 2016. e-Pub 2016. PMID: 27663436.
4. Shaitelman SF, Stauder MC, Allen PK, Reddy S, Lakoski SG, Atkinson BJ, Moulder S, Reddy J, Amaya D, Guerra W, Ueno NT, Caudle AS, Tereffe W, Woodward WA. Impact of Statin Use on Outcomes in Triple-Negative Breast Cancer. Int J Radiat Oncol Biol Phys 96(2S):E48, 2016. PMID: 27674802.
5. Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367-74, 2016. e-Pub 2016. PMID: 27522517.
6. Le Du F, Fujii T, Park M, Liu D, Hsu L, Gonzalez-Angulo AM, Ueno NT. Impact of clinical trial on survival outcomes. Breast Cancer Res Treat 159(2):273-81, 2016. e-Pub 2016. PMID: 27530453.
7. Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst 108(8), 2016. e-Pub 2016. PMID: 27075851.
8. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534(7605):47-54, 2016. e-Pub 2016. PMID: 27135926.
9. Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. Int J Radiat Oncol Biol Phys 95(2):791-9, 2016. e-Pub 2016. PMID: 27055396.
10. Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget 7(19):28329-39, 2016. e-Pub 2016. PMID: 27078845.
11. Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget 7(14):18531-40, 2016. e-Pub 2016. PMID: 26921265.
12. Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol 29(4):330-46, 2016. e-Pub 2016. PMID: 26916073.
13. Ueno NT, Mamounas EP. Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat 156(3):427-40, 2016. e-Pub 2016. PMID: 27072366.
14. Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control 27(3):359-66, 2016. e-Pub 2016. PMID: 26797453.
15. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 21(1):21-7, 2016. e-Pub 2015. PMID: 26659222.
16. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One 11(1):e0145534, 2016. e-Pub 2016. PMID: 26752563.
17. Trapé AP, Liu S, Cortes AC, Ueno NT, Gonzalez-Angulo AM. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. J Cancer 7(8):947-56, 2016. e-Pub 2016. PMID: 27313785.
18. Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer 7(9):1095-104, 2016. e-Pub 2016. PMID: 27326253.
19. Le Du F, Gonzalez-Angulo AM, Park M, Liu DD, Hortobagyi GN, Ueno NT. Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. Clin Breast Cancer 15(6):458-66, 2015. e-Pub 2015. PMID: 26233757.
20. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 2015. e-Pub 2015. PMID: 26348887.
21. Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J, Saso H, Smith PD, Dalby KN, Ueno NT. MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14(12):2773-81, 2015. e-Pub 2015. PMID: 26384399.
22. Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 1(9):1-8, 2015. e-Pub 2015. PMID: 26402167.
23. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT. Antitumor Activity of KW-2450 Against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther 14(12):2687-99, 2015. e-Pub 2015. PMID: 26443806.
24. Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat 154(3):495-508, 2015. e-Pub 2015. PMID: 26590814.
25. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, Li Y, Su X, Lucci A. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst 107(11), 2015. e-Pub 2015. PMID: 26374427.
26. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. PMID: 26486734.
27. Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer 113(7):1003-9, 2015. e-Pub 2015. PMID: 26393887.
28. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 90(8):996-1000, 2015. e-Pub 2015. PMID: 26211600.
29. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall Survival Differences Between Patients with Inflammatory and Noninflammatory Breast Cancer Presenting with Distant Metastasis at Diagnosis. Breast Cancer Res Treat 152(CNCR-15-0313):407-16, 2015. e-Pub 2015. PMID: 26017070.
30. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. e-Pub 2015. PMID: 26092296.
31. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol 38(3):242-7, 2015. e-Pub 2013. PMID: 23648437.
32. Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol 9(6):1155-68, 2015. e-Pub 2015. PMID: 25769405.
33. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget 6(15):12890-12908, 2015. e-Pub 2015. PMID: 25973541.
34. Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward WA. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys 91(5):1072-80, 2015. PMID: 25832697.
35. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 113(2):593-8, 2015. e-Pub 2014. PMID: 25373787.
36. Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, Krishnamurthy S, Gong Y, Levy LB, Buchholz T, Ueno NT, Klopp A, Woodward WA. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res 17(1):42, 2015. e-Pub 2015. PMID: 25887413.
37. Kai M, Kogawa T, Liu DD, Fouad TM, Kai K, Niikura N, Hsu L, Willey JS, Theriault RL, Valero V, Ueno NT. Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. Clin Breast Cancer 15(1):37-42, 2015. e-Pub 2014. PMID: 25258308.
38. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. e-Pub 2014. PMID: 25605252.
39. Chang EI, Chang EI, Ito R, Zhang H, Nguyen AT, Skoracki RJ, Hanasono MM, Crosby MA, Ueno NT, Hunt KK. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. Plast Reconstr Surg 135(2):262e-9e, 2015. PMID: 25626809.
40. Xie X, Tang H, Pengliu , Kong Y, Wu M, Xiao X, Yang L, Gao J, Wei W, Lee J, Bartholomeusz C, Ueno NT, Xie X. Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett 356(2 Pt B):374-81, 2015. e-Pub 2014. PMID: 25304382.
41. Le Du F, Ueno NT. Targeted therapies in triple-negative breast cancer: failure and future. Womens Health (Lond) 11(1):1-5, 2015. PMID: 25581048.
42. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 17(1):2, 2015. e-Pub 2015. PMID: 25572591.
43. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. e-Pub 2015. PMID: 25767600.
44. Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM. Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One 10(7):e0132710, 2015. e-Pub 2015. PMID: 26207636.
45. Kato S, Moulder SL, Ueno NT, Wheler JJ, Meric-Bernstam F, Kurzrock R, Janku F. Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience 2(6):576-80, 2015. e-Pub 2015. PMID: 26244164.
46. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer 6(12):1306-19, 2015. e-Pub 2015. PMID: 26640591.
47. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res 20(20):5265-71, 2014. e-Pub 2014. PMID: 25172932.
48. Hayashi N, Manyam GC, Gonzalez-Angulo AM, Niikura N, Yamauchi H, Nakamura S, Hortobágyi GN, Baggerly KA, Ueno NT. Reverse-Phase Protein Array for Prediction of Patients at Low Risk of Developing Bone Metastasis From Breast Cancer. Oncologist 19(9):909-14, 2014. e-Pub 2014. PMID: 25117064.
49. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16(5):440, 2014. e-Pub 2014. PMID: 25223629.
50. Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat 146(2):259-72, 2014. e-Pub 2014. PMID: 24916181.
51. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Transl Med 3(7):849-56, 2014. e-Pub 2014. PMID: 24833589.
52. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. J Clin Oncol 32(19):2018-24, 2014. e-Pub 2014. PMID: 24888808.
53. Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA. Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining. Clin Breast Cancer 14(3):e81-8, 2014. e-Pub 2013. PMID: 24461456.
54. Gong Y, Wei W, Wu Y, Ueno NT, Huo L. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer 120(12):1775-9, 2014. e-Pub 2014. PMID: 24634055.
55. Fouad T, El-Zein R, Ueno NT. Risk Factors for Inflammatory Breast Cancer and Other Invasive Breast Cancers. Breast Diseases 25(2):124, 2014.
56. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 2014. e-Pub 2014. PMID: 24510381.
57. Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 7(2):488-500, 2014. e-Pub 2014. PMID: 24703838.
58. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 25(2):358-65, 2014. e-Pub 2013. PMID: 24299959.
59. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2014. e-Pub 2013. PMID: 24351399.
60. Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene 33(4):440-8, 2014. e-Pub 2013. PMID: 23376849.
61. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2(+) Inflammatory Breast Cancer. PLoS One 9(1):e83113, 2014. e-Pub 2014. PMID: 24416156.
62. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus 3:166, 2014. e-Pub 2014. PMID: 24711988.
63. Fouad TM, Kogawa T, Reuben JM, Ueno NT. The role of inflammation in inflammatory breast cancer. Adv Exp Med Biol 816:53-73, 2014. PMID: 24818719.
64. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo AM, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1):58, 2014. e-Pub 2014. PMID: 25051981.
65. Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J Cancer 5(9):745-53, 2014. e-Pub 2014. PMID: 25368674.
66. Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT. (18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 40(12):1809-16, 2013. e-Pub 2013. PMID: 23877633.
67. Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, Ueno NT, Yamauchi H. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clin Breast Cancer 13(6):460-4, 2013. e-Pub 2013. PMID: 24084032.
68. Niikura N, Odisio BC, Tokuda Y, Symmans FW, Hortobagyi GN, Ueno NT. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol 10(12):711-9, 2013. e-Pub 2013. PMID: 24145987.
69. Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 5(4), 2013. PMID: 24416469.
70. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Res 73(21):6516-25, 2013. e-Pub 2013. PMID: 24014597.
71. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clin Cancer Res 19(19):5533-40, 2013. e-Pub 2013. PMID: 23948975.
72. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: An integrated analysis of three distinct Affymetrix gene expression data sets. Clin Cancer Res 19(17):4685-4696, 2013. e-Pub 2013. PMID: 23396049.
73. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant 48(8):1056-64, 2013. e-Pub 2013. PMID: 23419433.
74. Zhang W, Kai K, Ueno NT, Qin L. A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. Cancer Hallm 1(2-3):59-66, 2013. PMID: 25309822.
75. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: A cohort study. Br J Cancer 109(2):318-24, 2013. e-Pub 2013. PMID: 23820253.
76. Woodward WA, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M, Vermeulen P, Dirix L, Viens P, van Laere S, Bertucci F, Reuben JM, Ueno NT. Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat 138(3):761-72, 2013. e-Pub 2013. PMID: 23568481.
77. Hayashi N, Costelloe CM, Hamaoka T, Wei C, Niikura N, Theriault RL, Hortobagyi GN, Madewell JE, Ueno NT. A Prospective Study of Bone Tumor Response Assessment in Metastatic Breast Cancer. Clin Breast Cancer 13(1):24-30, 2013. e-Pub 2012. PMID: 23098575.
78. Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat 137(2):523-31, 2013. e-Pub 2012. PMID: 23184079.
79. Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley TN, Li L, Orton D, McMurray JS, Hang BI, Lee E, Klopp AH, Ueno NT, Reuben JM, Krishnamurthy S, Woodward WA. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8(8):e71508, 2013. e-Pub 2013. PMID: 24013655.
80. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
81. Cheng YC, Rondón G, Anderlini P, Khouri IF, Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer 4(8):679-85, 2013. e-Pub 2013. PMID: 24155780.
82. Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer 4(9):697-702, 2013. e-Pub 2013. PMID: 24312139.
83. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 15(6):R112, 2013. e-Pub 2013. PMID: 24274653.
84. Song Y, Zhang Y, Bernard PE, Reuben JM, Ueno NT, Arlinghaus RB, Zu Y, Qin L. Multiplexed volumetric bar-chart chip for point-of-care diagnostics. Nat Commun 3:1283, 2012. PMID: 23250413.
85. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA. Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells through WNT/β-catenin Signaling. Stem Cells 30(11):2366-77, 2012. e-Pub 2012. PMID: 22961641.
86. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther 11(11):2526-34, 2012. e-Pub 2012. PMID: 22973057.
87. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136(2):331-45, 2012. e-Pub 2012. PMID: 23073759.
88. Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant 47(11):1455-8, 2012. e-Pub 2012. PMID: 22465977.
89. Zhang W, Kai K, Choi DS, Iwamoto T, Nguyen YH, Wong H, Landis MD, Ueno NT, Chang J, Qin L. Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proc Natl Acad Sci U S A 109(46):18707-12, 2012. e-Pub 2012. PMID: 23112172.
90. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. Int J Radiat Oncol Biol Phys 83(5):1381-6, 2012. e-Pub 2012. PMID: 22284689.
91. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 12(4):264-9, 2012. e-Pub 2012. PMID: 22591634.
92. Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. Metastasis in the breast mimicking inflammatory breast cancer. J Clin Oncol 30(22):e202-6, 2012. e-Pub 2012. PMID: 22734030.
93. Simón J, Frank RK, Crump DK, Erwin WD, Ueno NT, Wendt RE. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical. Nucl Med Biol 39(6):770-6, 2012. e-Pub 2012. PMID: 22459336.
94. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer 19(3):191-9, 2012. e-Pub 2011. PMID: 21567170.
95. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. Leuk Lymphoma 53(6):1239-41, 2012. e-Pub 2012. PMID: 22132837.
96. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23(5):1144-50, 2012. e-Pub 2011. PMID: 21965473.
97. Bartholomeusz, C, Lee, J. Ueno NT. PEA-15 (phosphoprotein enriched in astrocytes 15). Atlas of Genetics and Cytogenetics in Oncology in Hematology 16(10):732, 2012.
98. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of anti tumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer 118(8):2039-47, 2012. e-Pub 2011. PMID: 22139648.
99. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 17(2):96-104, 2012. e-Pub 2011. PMID: 21671160.
100. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 2012. e-Pub 2011. PMID: 21765048.
101. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J Clin Oncol 30(7):729-34, 2012. e-Pub 2012. PMID: 22291085.
102. Rl A, K S, Ueno NT, S K, W W, R el-Z, Am B. Epidemiological risk factors associated with inflammatory breast cancer triple negative subtype. Cancer Epidemiol Biomarkers Prev 21(3):564, 2012. e-Pub 2012. PMID: 22337546.
103. Dutta B, Pusztai L, Qi Y, André F, Lazar V, Bianchini G, Ueno NT, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 106(6):1107-16, 2012. e-Pub 2012. PMID: 22343619.
104. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. J Clin Oncol 30(6):593-9, 2012. e-Pub 2011. PMID: 22124109.
105. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK 1/2 Inhibitor selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-dependent Manner in a Mouse Xenograft Model. Mol Cancer Ther 11(2):360-9, 2012. e-Pub 2011. PMID: 22144664.
106. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol 17(1):55-62, 2012. e-Pub 2011. PMID: 21607830.
107. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. Oncologist 17(2):233-8, 2012. e-Pub 2012. PMID: 22282904.
108. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist 17(7):891-9, 2012. e-Pub 2012. PMID: 22584436.
109. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 3:369-80, 2012. e-Pub 2012. PMID: 23074378.
110. Komatsu H, Hayashi N, Suzuki K, Yagasaki K, Iioka Y, Neumann J, Nakamura S, Ueno NT. Guided self-help for prevention of depression and anxiety in women with breast cancer. ISRN Nurs 2012:716367, 2012. e-Pub 2012. PMID: 23150835.
111. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 2011. e-Pub 2011. PMID: 21713757.
112. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol 16(5):596-600, 2011. e-Pub 2011. PMID: 21210173.
113. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 122(3):641-7, 2011. e-Pub 2011. PMID: 21652059.
114. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 29(24):3224-31, 2011. e-Pub 2011. PMID: 21768454.
115. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29(24):3214-23, 2011. e-Pub 2011. PMID: 21768471.
116. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 129(2):417-23, 2011. e-Pub 2010. PMID: 20857493.
117. Imamura CK, Ueno NT. Health services: How can we address cancer care after a natural disaster?. Nat Rev Clin Oncol 8(7):387-8, 2011. e-Pub 2011. PMID: 21647194.
118. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. PMID: 21558518.
119. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819-26, 2011. e-Pub 2010. PMID: 21509759.
120. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515-23, 2011. e-Pub 2010. PMID: 20603440.
121. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2011. e-Pub 2010. PMID: 21153052.
122. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. Oncologist 16(2):155-64, 2011. e-Pub 2011. PMID: 21266401.
123. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. Oncologist 16(6):772-82, 2011. e-Pub 2011. PMID: 21632453.
124. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3):R67, 2011. e-Pub 2011. PMID: 21699723.
125. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. Oncologist 16(7):956-65, 2011. e-Pub 2011. PMID: 21712485.
126. Komatsu H, Nakayama K, Togari T, Suzuki K, Hayashi N, Murakami Y, Iioka Y, Osaka W, Yagasaki K, Nakamura S, Neumann J, Ueno NT. Information sharing and case conference among the multidisciplinary team improve patients' perceptions of care. Open Nurs J 5:79-85, 2011. e-Pub 2011. PMID: 22135715.
127. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist 16(12):1675-83, 2011. e-Pub 2011. PMID: 22147002.
128. Bregni M, Childs RW, Ueno NT. 4th Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) Meeting. J Cancer 2:307-8, 2011. e-Pub 2011. PMID: 21716846.
129. Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2:324-8, 2011. e-Pub 2011. PMID: 21716849.
130. Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 16(8):1111-9, 2011. e-Pub 2011. PMID: 21765193.
131. Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT. Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. J Cancer 2:435-42, 2011. e-Pub 2011. PMID: 21850211.
132. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol 21(12):2348-55, 2010. e-Pub 2010. PMID: 20439340.
133. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol 100(3):449-57, 2010. e-Pub 2010. PMID: 20455002.
134. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641-51, 2010. e-Pub 2010. PMID: 20808302.
135. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹° p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther 9(11):3090-9, 2010. e-Pub 2010. PMID: 21045138.
136. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Ueno NT, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351-75, 2010. e-Pub 2010. PMID: 20959401.
137. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer 103(9):1331-4, 2010. e-Pub 2010. PMID: 20877352.
138. Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J. ABC conceptual model of effective multidisciplinary cancer care. Nat Rev Clin Oncol 7(9):544-7, 2010. e-Pub 2010. PMID: 20603648.
139. Cheng YC, Ueno NT. Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal?. Womens Health (Lond Engl) 6(4):481-5, 2010. PMID: 20597609.
140. Yamauchi H, Ueno NT. Targeted Therapy in Inflammatory Breast Cancer. Cancer 116(S11):2758-2759, 2010. PMID: 20503407.
141. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. Int J Cancer 1:80-92, 2010.
142. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J 16(3):327-30, 2010. e-Pub 2010. PMID: 20408820.
143. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub 2010. PMID: 20423989.
144. Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol 7(3):127-8, 2010. PMID: 20190792.
145. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76(3):889-95, 2010. PMID: 20159363.
146. Sugiyama N, Takashima A, Hashimoto H, Osato Y, Kitayma S, Sato H, Ueno NT. Introducing Multidisciplinary Team Practice― Through Our Experience Gained from Visiting MD Anderson Cancer Center. Jpn J Cancer Chemother 37:753-757, 2010.
147. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 2010. e-Pub 2010. PMID: 20215547.
148. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 102(4):651-7, 2010. e-Pub 2010. PMID: 20104228.
149. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 2010. e-Pub 2009. PMID: 19602564.
150. Niikura N, Ueno NT. The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer. J Cancer 1:51-3, 2010. e-Pub 2010. PMID: 20842224.
151. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9:180, 2010. e-Pub 2010. PMID: 20615238.
152. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-34, 2009. e-Pub 2009. PMID: 19998065.
153. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol 5(10):1585-603, 2009. PMID: 20001797.
154. Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol 20(11):1824-8, 2009. e-Pub 2009. PMID: 19556320.
155. Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant 15(11):1465-74, 2009. PMID: 19822307.
156. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15(21):6639-48, 2009. e-Pub 2009. PMID: 19825949.
157. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A Novel hTERT Promoter-driven E1A Therapeutic for Ovarian Cancer. Molecular Cancer Therapeutics Aug 8(8)(8):2375-82, 2009. e-Pub 2009. PMID: 19671744.
158. Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt Iii RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 9(3):173-7, 2009. PMID: 19661041.
159. Kai K, Nagano O, Sugihara E, Arima Y, Sampetrean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H, Saya H. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell moden. Cancer Sci, 2009. e-Pub 2009. PMID: 19737148.
160. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606-14, 2009. PMID: 19482249.
161. Yamauchi H, LaFortue T, Ueno NT. Lapatinib in the Treatment of Breast Cancer. Clinical Medicine: Therapeutics 1(1):513-526, 2009.
162. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 68(22):9311-17, 2008. PMID: 19010903.
163. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 2008. PMID: 18411419.
164. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Hematologica-the Hematology Journal 93(2):257-64, 2008. PMID: 18223284.
165. Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nature Clinical Practice Oncology 5(2):78-89, 2008. PMID: 18235440.
166. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Seminars In Oncology 35(1):64-71, 2008. PMID: 18308147.
167. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic Hematopoietic Cell Transplantation for Metastatic Breast Cancer. Bone Marrow Transplant 41(6):537-45, 2008. PMID: 18084340.
168. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics 7(7):1846-50, 2008. PMID: 18644997.
169. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67(12):5779-88, 2007. PMID: 17575145.
170. Itamochi H, Kigawa J, Kanamori Y, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapy 6:227-235, 2007.
171. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. Clin Breast Cancer 7(6):471-479, 2007. PMID: 17386124.
172. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 13(8):975-985, 2007. PMID: 17640602.
173. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of Breast Cancer Cells to Erlotinib Depends on Cyclin-Dependent Kinase 2 Activity. Molecular Cancer Therapeutics 6(8):2168-2177, 2007. PMID: 17671085.
174. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110(7):1436-1444, 2007. PMID: 17694554.
175. Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res 9(4):R41, 2007. PMID: 17612393.
176. Nakayama K, Ueno NT. American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. J Clin Oncol 24(33):5334-5; author reply 5337-8, 2006. PMID: 17114671.
177. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther 5:1593-601, 2006. PMID: 16818519.
178. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24:2910-6, 2006. PMID: 16782931.
179. Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther 13(5):451-9, 2006. PMID: 16294215.
180. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37:929-35, 2006. PMID: 16565737.
181. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1):79-90, 2006. PMID: 16170361.
182. Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 38:393-394, 2006.
183. Bregni M, Ueno NT, Childs R. The Second International Meeting on Allogeneic Transplantation in Solid Tumors. Bone Marrow Transplant 38(8):527-537, 2006. PMID: 16953213.
184. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 65(18):8406-13, 2005. PMID: 16166319.
185. Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol Cancer Ther 4(7):1039-46, 2005. PMID: 16020661.
186. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplantation 35(10):943-51, 2005. PMID: 15806128.
187. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-14, 2005. PMID: 15682071.
188. Cheng YC, Tannir N, Champlin RE, Ueno NT. Allogeneic hematopoietic stem-cell transplantation for metastatic renal cell carcinoma. Kidney Caner J 3:11-20, 2005.
189. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90:1725-1726, 2005.
190. Ueno NT. CNS from a physician's perspective. Rinsho kango 31(11):1660-1662, 2005.
191. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10(11):794-804, 2004. PMID: 15505610.
192. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 34(6):511-4, 2004. PMID: 15273710.
193. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno NT, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865-72, 2004. PMID: 15090449.
194. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942-53, 2004. PMID: 15254062.
195. Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 97(2):357-69, 2004. PMID: 15196762.
196. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22(12):2419-23, 2004. PMID: 15197204.
197. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64(11):3981-6, 2004. PMID: 15173011.
198. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64(7):2502-8, 2004. PMID: 15059905.
199. Sudo T, Ueno NT, Saya H. Functional analysis of APC-Cdh1. Methods Mol Biol 281:189-98, 2004. PMID: 15220530.
200. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 2003. PMID: 12881308.
201. Cheng YC, Ueno NT. Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review. Nippon Rinsho 61(9):1619-34, 2003. PMID: 14515734.
202. Trent JC, Charnsangavej C, Shah H, Giralt S, Ueno NT. Hepatic haematoma after allogeneic transplantation. Br J Haematol 122(5):694, 2003. PMID: 12930380.
203. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31(12):1157-63, 2003. PMID: 12796796.
204. Montemurro F, Rondon G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant 9(5):330-40, 2003. PMID: 12766883.
205. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno NT, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park) 17(1):94-100; discussion 103-7, 2003. PMID: 12599934.
206. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62(22):6712-6, 2002. PMID: 12438271.
207. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119(1):131-4, 2002. PMID: 12358917.
208. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30(6):367-73, 2002. PMID: 12235521.
209. Montemurro F, Rondon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29(10):861-6, 2002. PMID: 12058236.
210. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 13(3):450-9, 2002. PMID: 11996478.
211. Cheng, YC, Ueno NT. Nonmyeloablative Allogeneic Peripheral Blood Progenitor Cell Transplantation for Metastatic Breast Cancer and Metastatic Renal Cell Carcinoma: The M. D. Anderson Cancer Center Experience. Haematologica 87(6):6-9, 2002.
212. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 8(10):550-6, 2002. PMID: 12434950.
213. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 2001. PMID: 11751494.
214. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno NT, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92(7):1775-82, 2001. PMID: 11745249.
215. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J 7(5):413-20, 2001. PMID: 11693900.
216. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 67(4):227-33, 2001. PMID: 11443634.
217. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 28(3):271-5, 2001. PMID: 11535995.
218. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 2001. PMID: 11454891.
219. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno NT, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27(12):1221-5, 2001. PMID: 11548839.
220. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno NT, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 27 Suppl 2:S13-22, 2001. PMID: 11436116.
221. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 27:877-881, 2001. PMID: 11477447.
222. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 27(8):821-8, 2001. PMID: 11477439.
223. Shaikh ZH, Ueno NT, Kontoyiannis DP. Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transpl Infect Dis 3(1):29-33, 2001. PMID: 11429037.
224. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-7, 2001. PMID: 11157478.
225. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer 8(4):285-93, 2001. PMID: 11791119.
226. Hortobagyi GN, Ueno NT, Hung MC. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins. J Clin Oncol 19:4183-4184, 2001.
227. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno NT, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111(1):18-29, 2000. PMID: 11091179.
228. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, McLaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplantation 26(6):615-20, 2000. PMID: 11041566.
229. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno NT, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 2000. PMID: 10849525.
230. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant 6(2A):190-7, 2000. PMID: 10816027.
231. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6(1):250-9, 2000. PMID: 10656456.
232. Hung M, Hortobagyi G, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biology 465:171-180, 2000.
233. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am 13(5):1041-57, vii-viii, 1999. PMID: 10553260.
234. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 24(7):763-8, 1999. PMID: 10516680.
235. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Korbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 94(4):1465-70, 1999. PMID: 10438735.
236. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Korbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 10(5):527-32, 1999. PMID: 10416001.
237. Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MC. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. Oncol Rep 6(2):257-62, 1999. PMID: 10022986.
238. Ueno NT, Hortobagyi GN, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res 101:133-56, 1999. PMID: 10800648.
239. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S.. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematology/Oncology Clinics of North America 12:1041-1057, 1999.
240. Ueno NT, Amato RJ, Ro JJ, Weber RS. Primary malignant teratoma of the thyroid gland: report and discussion of two cases. Head Neck 20(7):649-53, 1998. PMID: 9744468.
241. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno NT, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16(8):2817-24, 1998. PMID: 9704734.
242. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16(3):986-93, 1998. PMID: 9508181.
243. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15(8):953-60, 1997. PMID: 9285690.
244. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 11(8):1386-90, 1997. PMID: 9264399.
245. Ueno NT, Wasaff B, Hortobagyi G, Buzdar A. Combined modality approach for the treatment of inflammatory breast carcinoma: Twenty-year experience of M. D. Anderson Cancer Center. Cancer Chemoth Pharmacol 40:321-329, 1997.
246. Ueno NT, Kiyokawa N, Hung M. Growth suppression of low HER-2/neu-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. Oncol Report 3:509-511, 1996.
247. Ueno NT, Zukiwski AA. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma. J Clin Oncol 18:358-62, 1995. PMID: 7625380.
248. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2):81-7. e-Pub 2009. PMID: 19448681.
249. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol 27(27):1-9. e-Pub 2009. PMID: 19451443.
250. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 11(1):R12. e-Pub 2009. PMID: 19239702.
251. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6(7):387-94. e-Pub 2009. PMID: 19468291.
252. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. Mol Endocrinol. e-Pub 2010. PMID: 20081105.
253. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. e-Pub 2010. PMID: 21117228.
254. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Hortobagyi GN, Ueno NT. Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria. Br J Cancer. e-Pub 2010. PMID: 20664594.
255. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. J Nucl Med. e-Pub 2010. PMID: 20660382.
256. Lee J, Bartholomeusz C, Krishnamurthy S, Liu P, Saso H, LaFortune TA, Hortobagyi GN, Ueno NT. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking β-catenin. Oncogenesis. e-Pub 2012. PMID: 23552738.
257. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thomb Haemost 6(113):2. e-Pub 2014.

Invited Articles

1. Lee J, Lim B, Ueno NT. EDGE Preclinical Solutions Program at MD Anderson Aims to Overcome Challenges of Preclinical Research for Breast Cancer Early Drug Development. Oncology Times, 2015. e-Pub 2015.
2. Nakayama K, Ueno NT. American Society of Clin Oncol recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. J Clin Oncol 24:5334-5335, 2006.
3. Ueno NT, Cheng YC. Review of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer. J Clin Oncol, 2004.
4. Ueno NT,. Allogeneic transplantation in solid tumor. Rinsyoui 27:48-54, 2001.
5. Ueno NT, Champlin R. Allogeneic transplantation in metastatic breast cancer; rationale for use of nonmyeloablative preparative regimens. Seminars in Breast Cancer 3:176, 2000.
6. Ueno NT,. Profiles in Oncology Social Media. Oncology Times 32(10). e-Pub 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Ueno NT, Buzdar A, Hortobagyi G. Inflammatory Breast Cancer, 1995.

Other Articles

1. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN, Ueno NT Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther 12(6):1099-111, 2013. PMID: 23543364.
2. Ueno NT Targeting the Epithelial-mesenchymal Transition to Reduce Metastasis of Inflammatory Breast Cancer. Breast Cancer Symposium Proceeding, 2010.
3. Ueno NT More Evidence Is Needed: Perspective from a Frustrated Cancer Doctor/Researcher/Patient. Oncology Times 31(22):4-6, 2009.
4. Ueno NT M. D. Anderson Cancer Center Medical Exchange Program. Oncology:1-7, 2008.
5. Ueno NT How to receive ultimate medical care. Patient is the most important player. Nami 31:338-339, 2007.
6. Ueno NT Role of clinical pharmacist in cancer care. Nursing Today 20, 2007.
7. Ueno NT Importance of Nursing Research. Nursing Today 19(6):62-63, 2004.
8. Ueno NT Importance of obtaining concensus among medical staff. Nursing Today 19(5):66-67, 2004.
9. Ueno NT Multi-disciplinary care expands the role of nurses. Nursing Today 19(8):64-65, 2004.
10. Ueno NT Role of advanced nurse practitioners and research nurses. Nursing Today 19(7):58-59, 2004.
11. Ueno NT The role of transplantation in metastatic breast cancer. Clinical Issues & Therapeutic Advances. USA:4-5, 2004.
12. Ueno NT Road to Medical Oncologist. Kani 30:47-51, 2003.
13. Childs R, Mason J, Ueno NT Stem Cell Transplants for Patients with Kidney Cancer. Blood and Marrow Transplant Newsletter 13(56), 2002.
14. Ueno NT Cancer Treatment at The University of Texas M. D. Anderson Cancer Center. Gulf Stream Japan Business Association of Houston Newsletter 27, 2002.
15. Ueno NT River next to Pittsburgh. Medical Student 3(6):123-129, 1993.
16. Ueno NT River next to Pittsburgh. Medical Student 2(6):119-123, 1993.

Editorials

1. Ueno NT, Child RQ. What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. Biology of Blood and Marrow Transplantation 13:31-33, 2007.
2. Ueno NT, Cheng YC. The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy. Bone Marrow Transplant 38:711-771, 2006.
3. Nakayama K, Ueno NT. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. Breast Disease 16, 2005.
4. Ueno NT, Shpall EJ, Champlin RE, Jones, RB. Graft-vs-Breast Cancer Effect by Allogeneic Hematopoietic Stem Cell Transplantation: A Possible New Frontier. J Clin Oncol 22:3846-3847, 2004.
5. Ueno NT, Cheng YC. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. Breast Disease 15:76, 2004.
6. Ueno NT, Cheng YC, Shpall EJ, Champlin RE. Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer: New Hope. Breast Disease 15, 2004.

Book Chapters

1. Ueno NT, Fouad TM, Kogawa T, Reuben JM. The Role of Inflammation in Inflammatory Breast Cancer. In: Inflammation and Cancer; Advances in Experimental Medicine and Biology. Springer Basel, 53, 2014.
2. Costelloe CM, Ueno NT, Lin PP, Yu TK, Hayashi N, Madewell JE. Bone Metastases. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders: Philadelphia, 2012.
3. Hayashi N, Onishi T, Ueno NT, Lewis V. Management of Osseous Metastases and Impending Fractures. In: Advanced Therapy of Breast Disease. Third. PMPH-USA: Shelton, 2012.
4. Aikou T, Kitagawa Y, Uenosono Y, Natsugoe S, Bilchik AJ, Ueno NT. Gastrointestinal Cancer and the Lymphatic System: Patterns of Micrometastasis and Lymphatic Mapping with Clinical Outcome. In: From Local Invasion to Metastatic Cancer. Springer, 2009.
5. Asahi S, Ueno NT. Drug Therapy in Breast Cancer. In: Drug Therapy in Breast Cancer: Japan, 141, 2009.
6. Ueno NT, Munker R, Atkinson K. Therapeutic decision making in stem cell transplantation for breast cancer. In: THE BMT DATA BOOK 2ND EDITION. 2nd. Cambridge University Press: USA, 2008.
7. Ueno NT. Emphasis of increase patient satisfaction at The University of Texas M. D. Anderson Cancer Center. In: Medical Student Perspective of Cancer Medicine. Sentan Igakusya: Japan, Chapter I, pages 16-20; Chapter 2, pages 24-40, 2008.
8. Ueno NT. Role of Medical Oncologist at M. D. Anderson Caner Center. In: Medical Student Perspective of Cancer Medicine. Sentan Igakusya: Tokyo, Chapter 1, Pages 16-20, 2008.
9. Ueno NT. What I have seen as a doctor. What I noticed after being a patient. In: Facing your daily life (Kurashi-to-mukiau). Astra Zeneca: Japan, 10-15, 2008.
10. Aikou T, Kitagawa Y, Uenosono Y, Natsugoe S, Bilchik A, Ueno NT. Gastrointestinal Cancer and the Lymphatic System: Patterns of Micrometastasis and Lymphatic Mapping with Clinical Outcome. In: From Local Invasion to Metastatic Cancer. Springer, 2008.
11. Nakayama K, Ueno NT. Therapy-related infertility in hematological diseases. In: [Rinshō ketsueki] The Japanese Journal of Clinical Hematology. 3, 182-92, 2008.
12. Ueno NT, Wolf JK, Gershenson DM, Hortobagyi GN, Hung MC. Trials and Tribulations in Developing Clinical Trials of Gene Therapy: E1A for Breast or Ovarian Cancer. Gene Therapy for Cancer. In: Cancer Gene Therapy. Humana Press, 2007.
13. Ueno NT, Andreeff M, Champlin R. High-dose Chemotherapy as Treatment for High-risk Breast Primary and Metastatic Breast Cancer. In: Breast Cancer. New York Inc: NY, 2006.
14. Ueno NT, Hortobagyi G, Hung, M. Results from a Phase I Trial of E1A Gene Therapy in Breast and Ovarian Cancer: What's Next?. In: Breast Cancer Management: Application of evidence to patient care. Martin Dunitz, in press, 2002.
15. Ueno NT, Champlin R. High-dose Chemotherapy as Treatment for High-risk breast Primary and Metastatic Breast Cancer. In: Breast Cancer. M. D. Anderson Cancer Care Series. Springer-Verlag, 2001.
16. Ueno NT, Hortobagyi G, Hung, M. Monitoring molecular outcomes of E1A Gene therapy in breast and ovarian cancer. In: Breast Cancer Management: Application of evidence to patient care. Martin Dunitz, 209-219, 2000.
17. Ueno NT, Hortobagyi G, Champlin R. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. In: Advance in allogeneic hematopoietic stem cell transplantation. Kluwer Academic Publishers, 133-156, 1999.
18. Ueno NT, Hung M. E1A chemosensitization in cancer cells. In: Gene therapy; from molecular mechanisms to clinical applications. Gene Therapy Press, in press, 1999.
19. Hung, M, Ueno NT. Targeting HER-2/neu overexpression: Transcriptional repression of HER-2/neu by adenovirus type 5 E1A as a cancer gene therapy. In: Proceeding of the ''22nd congress of the international association for breast cancer research.", 85-95, 1998.
20. Ueno NT, Champlin R. Autologous Transplantation. In: Medical oncology, A Comprehensive Review. PRR, 151-165, 1996.
21. Ueno NT. Inflammatory Breast Cancer. In: MD Anderson manual of Medical Oncology Third Edition. McGraw-Hill Global Education Holdings, LLC.

Books (edited and written)

1. Ueno NT. Bone Management in Breast Cancer. In: Learning as a Team Series. Ed(s) Ueno NT, N Kouno, S Nakamura, N Hayashi. Shinohara Publication: Tokyo, Japan, 2012.
2. Cristofanilli M, Wiggins S, Taylor S, Bondy M, Dawood S, Valero V, Willey J, Barsky SH, Robertson FM, Yang WT, Gainer SM, Yamauchi H, Lucci A, Buchholz T, Bristol I, Woodward W, Yamauchi T, Goncalves A, Viens P, Chowdhury N, Swain S, Cheng YC, Lacerda L, Zhang D, Joglekar M, Van Golen KL, Chu K, Circo R, Wulfkuhle J, Luo AZ, Boley KM, Freiter EM, Liu H, Mandal PK, McMurray JS, Petricoin EF, Reuben JM, Lee BN, Vermeulen PB, Van Den Eynden G, Finetti P, Birnbaum D, Viens P, Bertucci F, Dirix LY, Van Laere SJ, Chaffanet M, Esteban M, Bradfield P, Ueno NT. Inflammatory Breast Cancer: An Update. Ed(s) Ueno NT, Cristofanilli M. Springer Dordrecht Heidelbert New York London: New York, 2012.
3. Ueno NT. Breast Cancer. In: MD Anderson Cancer Care Series. Ed(s) Hunt K, Robb G, Strom E, Ueno N. 2nd. Srpinger-Verlag: New York, NY, 2007.
4. Ueno NT. Saikouno-iryou-wo-ukerutameno-kanyaga ku (How to receive ultimate medical care). Koadansha, Alpha-Shinsho, 2006.
5. Ueno NT. Breast Cancer. In: Breast Cancer MD Anderson Care Series. Ed(s) Hunt K, Robb G, Strom E, Ueno N. First. Springer-Verlag: New York, NY, 2001.

Letters to the Editor

1. Saji S, Sato F, Ueno NT. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer. Nat Rev Clin Oncol 9, 2012.
2. Hortobagyi GN, Ueno NT, Hung MC. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins - In reply. Journal of Clinical Oncology 19: 4183-4184, 2001.
3. Ueno NT. Commentary for "High-dose chemotherapy with peripheral blood stem cell support for operable locally advanced noninflammatory carcinoma of the breast.". Breast diseases: a year book quarterly 11: 201-202, 2000.